Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Pfizer

Status: Completed

Conditions: Invasive Pneumococcal Disease

Treatments: Other: No intervention

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01128439

6096A1-4005

B1851042 (Other Identifier)

Details and patient eligibility

About

This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.

Full description

No sampling as no subjects are enrolled

Enrollment: 1 patient

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S pneumoniae from a normally sterile site in a member of the surveillance population.

Exclusion criteria

None

Trial design

1 participants in 1 patient group

1

Treatment:

Other: No intervention